-
1
-
-
0032463041
-
3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194
-
3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J. Pharmacol. Exp. Ther. 287 (1998) 187-197
-
(1998)
J. Pharmacol. Exp. Ther.
, vol.287
, pp. 187-197
-
-
Audinot, V.1
Newman-Tancredi, A.2
Gobert, A.3
Rivet, J.-M.4
Brocco, M.5
Lejeune, F.6
Gluck, L.7
Desposte, I.8
Bervoets, K.9
Dekeyne, A.10
Millan, M.J.11
-
2
-
-
34347335477
-
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study
-
Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., and Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68 (2007) 843-853
-
(2007)
J. Clin. Psychiatry
, vol.68
, pp. 843-853
-
-
Berman, R.M.1
Marcus, R.N.2
Swanink, R.3
McQuade, R.D.4
Carson, W.H.5
Corey-Lisle, P.K.6
Khan, A.7
-
4
-
-
55749106241
-
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia
-
Findling R.L., Robb A., Nyilas M., Forbes R.A., Jin N., Ivanova S., Marcus R., McQuade R.D., Iwamoto T., and Carson W.H. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am. J. Psychiatry AiA (2008) 1-10
-
(2008)
Am. J. Psychiatry
, vol.AiA
, pp. 1-10
-
-
Findling, R.L.1
Robb, A.2
Nyilas, M.3
Forbes, R.A.4
Jin, N.5
Ivanova, S.6
Marcus, R.7
McQuade, R.D.8
Iwamoto, T.9
Carson, W.H.10
-
5
-
-
62249205969
-
Long-term efficacy and safety of aripiprazole in children and adolescents with mania
-
Forbes A., Nyilas M., Loze J., Laughton J., Johnson B., Aurang C., Iwamoto T., Carson W.H., and Owen R. Long-term efficacy and safety of aripiprazole in children and adolescents with mania. Eur. Neuropsychopharmacol. 18 Suppl 4 (2008) S556-557
-
(2008)
Eur. Neuropsychopharmacol.
, vol.18
, Issue.SUPPL. 4
-
-
Forbes, A.1
Nyilas, M.2
Loze, J.3
Laughton, J.4
Johnson, B.5
Aurang, C.6
Iwamoto, T.7
Carson, W.H.8
Owen, R.9
-
7
-
-
6344253360
-
Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management
-
Haddad P.M., and Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64 (2004) 2291-2314
-
(2004)
Drugs
, vol.64
, pp. 2291-2314
-
-
Haddad, P.M.1
Wieck, A.2
-
8
-
-
0036738786
-
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
-
Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., and Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63 (2002) 763-771
-
(2002)
J. Clin. Psychiatry
, vol.63
, pp. 763-771
-
-
Kane, J.M.1
Carson, W.H.2
Saha, A.R.3
McQuade, R.D.4
Ingenito, G.G.5
Zimbroff, D.L.6
Ali, M.W.7
-
10
-
-
0034025771
-
2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia
-
2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 514-520
-
(2000)
Am. J. Psychiatry
, vol.157
, pp. 514-520
-
-
Kapur, S.1
Zipursky, R.2
Remington, G.3
Houle, S.4
-
11
-
-
0038585981
-
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania
-
Keck P.E.J., Marcus R., Tourkodimitris S., Ali M., Liebeskind A., Saha A., and Ingenito G. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry 160 (2003) 1651-1658
-
(2003)
Am. J. Psychiatry
, vol.160
, pp. 1651-1658
-
-
Keck, P.E.J.1
Marcus, R.2
Tourkodimitris, S.3
Ali, M.4
Liebeskind, A.5
Saha, A.6
Ingenito, G.7
-
14
-
-
33746101099
-
The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine
-
Kern R.S., Green M.F., Cornblatt B.A., Owen J.R., McQuade R.D., Carson W.H., Ali M., and Marcus R. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 187 (2006) 312-320
-
(2006)
Psychopharmacology
, vol.187
, pp. 312-320
-
-
Kern, R.S.1
Green, M.F.2
Cornblatt, B.A.3
Owen, J.R.4
McQuade, R.D.5
Carson, W.H.6
Ali, M.7
Marcus, R.8
-
16
-
-
0037382034
-
Functional effects of antipsychotic drugs: comparing clozapine with haloperidol
-
Lahti A.C., Holcomb H.H., Weiler M.A., Medoff D.R., and Tamminga C.A. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol. Psychiatry 53 (2003) 601-608
-
(2003)
Biol. Psychiatry
, vol.53
, pp. 601-608
-
-
Lahti, A.C.1
Holcomb, H.H.2
Weiler, M.A.3
Medoff, D.R.4
Tamminga, C.A.5
-
18
-
-
40949089056
-
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study
-
Marcus R.N., McQuade R.D., Carson W.H., Hennicken D., Fava M., Simon J.S., Trivedi M.H., Thase M.E., and Berman R.M. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 28 (2008) 156-165
-
(2008)
J. Clin. Psychopharmacol.
, vol.28
, pp. 156-165
-
-
Marcus, R.N.1
McQuade, R.D.2
Carson, W.H.3
Hennicken, D.4
Fava, M.5
Simon, J.S.6
Trivedi, M.H.7
Thase, M.E.8
Berman, R.M.9
-
19
-
-
0037410337
-
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials
-
Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., Saha A., Ali M., and Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 61 (2003) 123-136
-
(2003)
Schizophr. Res.
, vol.61
, pp. 123-136
-
-
Marder, S.R.1
McQuade, R.D.2
Stock, E.3
Kaplita, S.4
Marcus, R.5
Safferman, A.Z.6
Saha, A.7
Ali, M.8
Iwamoto, T.9
-
20
-
-
0020536004
-
Dopamine receptor antagonism by the novel antianxiety drug, buspirone
-
McMillen B.A., M, atthews R.T., Sanghera M.K., Shepard P.D., and German D.C. Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J. Neurosci. 3 (1983) 733-738
-
(1983)
J. Neurosci.
, vol.3
, pp. 733-738
-
-
McMillen, B.A.1
Matthews, R.T.2
Sanghera, M.K.3
Shepard, P.D.4
German, D.C.5
-
21
-
-
16644402581
-
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study
-
McQuade R.D., Stock E., Marcus R., Jody D., Gharbia N.A., Vanveggel S., Archibald D., and Carson W.H. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry 65 (2004) 47-56
-
(2004)
J. Clin. Psychiatry
, vol.65
, pp. 47-56
-
-
McQuade, R.D.1
Stock, E.2
Marcus, R.3
Jody, D.4
Gharbia, N.A.5
Vanveggel, S.6
Archibald, D.7
Carson, W.H.8
-
22
-
-
38049005307
-
Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis
-
Miller D.D., Eudicone J.M., Pikalov A., and Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J. Clin. Psychiatry 68 (2007) 1901-1906
-
(2007)
J. Clin. Psychiatry
, vol.68
, pp. 1901-1906
-
-
Miller, D.D.1
Eudicone, J.M.2
Pikalov, A.3
Kim, E.4
-
24
-
-
0033595283
-
3 receptor agonist
-
3 receptor agonist. Nature 400 (1999) 371-375
-
(1999)
Nature
, vol.400
, pp. 371-375
-
-
Pilla, M.1
Perachon, S.2
Sautel, F.3
Garrido, F.4
Mann, A.5
Wermuth, C.G.6
Schwartz, J.C.7
Everitt, B.J.8
Sokoloff, P.9
-
25
-
-
0038488945
-
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
-
Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., and Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60 (2003) 681-690
-
(2003)
Arch. Gen. Psychiatry
, vol.60
, pp. 681-690
-
-
Potkin, S.G.1
Saha, A.R.2
Kujawa, M.J.3
Carson, W.H.4
Ali, M.5
Stock, E.6
Stringfellow, J.7
Ingenito, G.8
Marder, S.R.9
-
26
-
-
0030271402
-
Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study
-
Semba J., Sakai M., Miyoshi R., Mataga N., Fukamauchi F., and Kito S. Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study. Neurochem. Int. 29 (1996) 435-442
-
(1996)
Neurochem. Int.
, vol.29
, pp. 435-442
-
-
Semba, J.1
Sakai, M.2
Miyoshi, R.3
Mataga, N.4
Fukamauchi, F.5
Kito, S.6
-
27
-
-
20344400385
-
Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic
-
Tadori Y., Miwa T., Tottori K., Burris K.D., Stark A., Mori T., and Kikuchi T. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur. J. Pharmacol. 515 (2005) 10-19
-
(2005)
Eur. J. Pharmacol.
, vol.515
, pp. 10-19
-
-
Tadori, Y.1
Miwa, T.2
Tottori, K.3
Burris, K.D.4
Stark, A.5
Mori, T.6
Kikuchi, T.7
-
28
-
-
35348854954
-
2 receptors between aripiprazole, bifeprunox and SDZ 208-912
-
2 receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur. J. Pharmacol. 574 (2007) 103-111
-
(2007)
Eur. J. Pharmacol.
, vol.574
, pp. 103-111
-
-
Tadori, Y.1
Kitagawa, H.2
Forbes, R.A.3
McQuade, R.D.4
Stark, A.5
Kikuchi, T.6
-
30
-
-
37249047375
-
Aripiprazole in the treatment of the psychosis prodrome
-
Woods S.W., Tully E.M., Walsh B.C., Hawkins K.A., Callahan J.L., Cohen S.J., Mathalon D.H., Miller T.J., and McGlashan T.H. Aripiprazole in the treatment of the psychosis prodrome. Br. J. Psychiatry 191 Suppl 51 (2007) s96-s101
-
(2007)
Br. J. Psychiatry
, vol.191
, Issue.SUPPL. 51
-
-
Woods, S.W.1
Tully, E.M.2
Walsh, B.C.3
Hawkins, K.A.4
Callahan, J.L.5
Cohen, S.J.6
Mathalon, D.H.7
Miller, T.J.8
McGlashan, T.H.9
|